newsfilter
← Latest News
ACCESS Newswire·

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme HOUSTON, TX / ACCESS